# ARSB

## Overview
The ARSB gene encodes the enzyme arylsulfatase B, a lysosomal enzyme that plays a critical role in the degradation of glycosaminoglycans (GAGs), specifically chondroitin 4-sulfate and dermatan sulfate. This enzyme is categorized as a sulfatase and is essential for maintaining cellular homeostasis by facilitating the breakdown and recycling of GAGs within lysosomes (Bartolomeo2012Pharmacological; Tobacman2022Profound). The ARSB gene is located on chromosome 5q14.1 and is expressed in various tissues, including the kidney, cervix, and heart (Tobacman2022Profound). Mutations in the ARSB gene can lead to Mucopolysaccharidosis type VI (MPS VI), a lysosomal storage disorder characterized by the accumulation of GAGs, resulting in a range of clinical manifestations (Aminzadeh2019Identification; Karageorgos2007Mutationala). The enzyme's activity is dependent on post-translational modifications, such as the conversion of a critical cysteine residue to formylglycine, which is necessary for its catalytic function (Tobacman2022Profound).

## Structure
The ARSB protein, also known as N-acetylgalactosamine-4-sulfatase, is a lysosomal enzyme involved in the degradation of glycosaminoglycans such as chondroitin 4-sulfate and dermatan sulfate. The primary structure of ARSB consists of 533 amino acids in its transcript variant 1 and 413 amino acids in its truncated transcript variant 2. The protein includes a signal peptide spanning amino acids 1-36, which is cleaved during translocation through the endoplasmic reticulum (ER) membrane (Garrido2008Maroteaux–Lamy; Tobacman2022Profound).

The secondary structure of ARSB features multiple alpha helices and beta sheets. The tertiary structure is characterized by complex folding, including glycosylation sites and disulfide bonds, with a molecular weight of 59,687 Da. The enzyme's active site contains a crucial cysteine residue, C91, which is post-translationally modified to formylglycine, essential for its catalytic activity (Ghosh2005Three‐Dimensional; Tobacman2022Profound).

ARSB's quaternary structure involves interactions with other molecules, and in some species, such as felines, it forms a homodimer due to an additional cysteine residue (Jackson1992Feline). The protein undergoes post-translational modifications, including glycosylation at four asparagine residues (Garrido2008Maroteaux–Lamy).

## Function
The ARSB gene encodes the enzyme N-acetylgalactosamine-4-sulfatase, also known as arylsulfatase B (ARSB), which is crucial for the degradation of glycosaminoglycans (GAGs) such as chondroitin 4-sulfate and dermatan sulfate. In healthy human cells, ARSB removes sulfate groups from these GAGs, a process essential for their proper breakdown and recycling within lysosomes (Bartolomeo2012Pharmacological; Tobacman2022Profound). This enzymatic activity is vital for maintaining cellular homeostasis and normal cellular functions, including cell signaling, transcription, differentiation, and metabolism (Tobacman2022Profound).

ARSB is widely distributed in human tissues, with high expression in the kidney, cervix, and heart. It is found in various cellular locations, including cell membranes, nuclei, and mitochondria, suggesting it acts in close proximity to its substrates in the extracellular matrix or at the membrane (Tobacman2022Profound). The enzyme's activity is dependent on post-translational modification by the formylglycine modifying enzyme (FGE), which converts a critical cysteine residue to formylglycine, enabling ARSB to bind and hydrolyze sulfate groups (Tobacman2022Profound).

ARSB's function is also linked to the regulation of insulin signaling and cellular metabolism, influencing processes such as cell migration, invasion, and proliferation (Tobacman2022Profound). Its activity is crucial for preventing the accumulation of sulfated GAGs, which can lead to various pathologies, including Mucopolysaccharidosis VI (MPS VI) (Tobacman2022Profound).

## Clinical Significance
Mutations in the ARSB gene lead to Mucopolysaccharidosis type VI (MPS VI), also known as Maroteaux-Lamy syndrome, a rare autosomal recessive lysosomal storage disorder. This condition is characterized by a deficiency in the enzyme arylsulfatase B, resulting in the accumulation of glycosaminoglycans such as dermatan sulfate and chondroitin sulfate in lysosomes (Aminzadeh2019Identification; Karageorgos2007Mutationala). Clinical manifestations of MPS VI include growth retardation, coarse facial features, joint stiffness, skeletal deformities, respiratory difficulties, corneal clouding, hepatosplenomegaly, and cardiac abnormalities (Tomanin2018Mucopolysaccharidosis; Karageorgos2007Mutationala). Unlike other mucopolysaccharidoses, MPS VI does not typically affect the central nervous system, and patients generally have normal neurological development (Karageorgos2007Mutationala).

The ARSB gene is highly heterogeneous, with over 140 different mutations identified, including missense, nonsense, deletions, insertions, and splice-site mutations (Aminzadeh2019Identification; Karageorgos2007Mutationala). The variability in mutations contributes to a wide spectrum of clinical phenotypes, ranging from severe to mild forms of the disease (Zanetti2013Molecular; Jurecka2012Molecular). Some mutations, such as p.Leu321Pro, are prevalent in specific populations, indicating possible founder effects (Kantaputra2014Clinical). Treatment options for MPS VI include enzyme replacement therapy and, less commonly, hematopoietic stem cell transplantation (Aminzadeh2019Identification).

## Interactions
Arylsulfatase B (ARSB) participates in several interactions with proteins and nucleic acids that influence cellular processes. ARSB regulates versican expression through transcriptional mechanisms involving galectin-3 and the AP-1 transcription factor complex. Silencing ARSB leads to increased nuclear c-Jun and c-Fos, components of AP-1, suggesting an interaction with these proteins. This interaction is crucial for the regulation of versican expression, as demonstrated by the binding of c-Fos and galectin-3 to the versican promoter (Bhattacharyya2013Arylsulfatase).

ARSB also interacts with the p38 MAPK signaling pathway. Exposure to the SARS-CoV-2 spike protein receptor-binding domain (SPRBD) results in a decline in ARSB expression mediated by phospho-p38 MAPK. This decline is associated with increased N-terminal phosphorylation of the Retinoblastoma protein (Rb), enhancing Rb-E2F1 binding and reducing E2F1-DNA binding. The ARSB promoter contains potential E2F1 binding sites, and the SPRBD-induced decline in ARSB expression is linked to reduced E2F1 binding to these sites (Bhattacharyya2024SARSCoV2).

In the context of chondroitin sulfate metabolism, ARSB silencing leads to increased CHST15 expression, mediated by the Wnt signaling pathway and involving phospho-p38 MAPK and Rac-1 GTPase. This suggests ARSB's role in modulating signaling pathways through interactions with these proteins (Bhattacharyya2020Increased).


## References


[1. (Aminzadeh2019Identification) Majid Aminzadeh, Nasrin Malekpour, and Pegah Ghandil. Identification of arylsulfatase b gene mutations and clinical presentations of iranian patients with mucopolysaccharidosis vi. Gene, 706:1–5, July 2019. URL: http://dx.doi.org/10.1016/j.gene.2019.04.050, doi:10.1016/j.gene.2019.04.050. This article has 6 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.gene.2019.04.050)

[2. (Bhattacharyya2020Increased) Sumit Bhattacharyya, Leo Feferman, Xiaorui Han, Ke Xia, Fuming Zhang, Robert J. Linhardt, and Joanne K. Tobacman. Increased chst15 follows decline in arylsulfatase b (arsb) and disinhibition of non-canonical wnt signaling: potential impact on epithelial and mesenchymal identity. Oncotarget, 11(24):2327–2344, June 2020. URL: http://dx.doi.org/10.18632/oncotarget.27634, doi:10.18632/oncotarget.27634. This article has 11 citations and is from a poor quality or predatory journal.](https://doi.org/10.18632/oncotarget.27634)

[3. (Ghosh2005Three‐Dimensional) Debashis Ghosh. Three‐Dimensional Structures of Sulfatases, pages 273–293. Elsevier, 2005. URL: http://dx.doi.org/10.1016/S0076-6879(05)00016-9, doi:10.1016/s0076-6879(05)00016-9. This article has 51 citations.](https://doi.org/10.1016/S0076-6879(05)00016-9)

[4. (Zanetti2013Molecular) Alessandra Zanetti, Neslihan Önenli-Mungan, Nursel Elcioglu, Mehmet Nuri Özbek, Deniz Kör, Elisabetta Lenzini, Maurizio Scarpa, and Rosella Tomanin. Molecular Analysis of Turkish Maroteaux-Lamy Patients and Identification of One Novel Mutation in the Arylsulfatase B (ARSB) Gene, pages 1–9. Springer Berlin Heidelberg, 2013. URL: http://dx.doi.org/10.1007/8904_2013_276, doi:10.1007/8904_2013_276. This article has 3 citations.](https://doi.org/10.1007/8904_2013_276)

[5. (Jurecka2012Molecular) Agnieszka Jurecka, Ewa Piotrowska, Loreta Cimbalistiene, Nina Gusina, Agnieszka Sobczyńska, Barbara Czartoryska, Kamila Czerska, Katrin Õunap, Grzegorz Węgrzyn, and Anna Tylki-Szymańska. Molecular analysis of mucopolysaccharidosis type vi in poland, belarus, lithuania and estonia. Molecular Genetics and Metabolism, 105(2):237–243, February 2012. URL: http://dx.doi.org/10.1016/j.ymgme.2011.11.003, doi:10.1016/j.ymgme.2011.11.003. This article has 24 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.ymgme.2011.11.003)

[6. (Bartolomeo2012Pharmacological) Rosa Bartolomeo, Elena V. Polishchuk, Nicola Volpi, Roman S. Polishchuk, and Alberto Auricchio. Pharmacological read‐through of nonsense arsb mutations as a potential therapeutic approach for mucopolysaccharidosis vi. Journal of Inherited Metabolic Disease, 36(2):363–371, September 2012. URL: http://dx.doi.org/10.1007/s10545-012-9521-y, doi:10.1007/s10545-012-9521-y. This article has 32 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s10545-012-9521-y)

[7. (Tobacman2022Profound) Joanne K. Tobacman and Sumit Bhattacharyya. Profound impact of decline in n-acetylgalactosamine-4-sulfatase (arylsulfatase b) on molecular pathophysiology and human diseases. International Journal of Molecular Sciences, 23(21):13146, October 2022. URL: http://dx.doi.org/10.3390/ijms232113146, doi:10.3390/ijms232113146. This article has 9 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms232113146)

[8. (Kantaputra2014Clinical) Piranit Nik Kantaputra, Hulya Kayserili, Yeliz Guven, Warissara Kantaputra, Mehmet C. Balci, Pranoot Tanpaiboon, Napaporn Tananuvat, Anusha Uttarilli, and Ashwin Dalal. Clinical manifestations of 17 patients affected with mucopolysaccharidosis type vi and eight novel arsb mutations. American Journal of Medical Genetics Part A, 164(6):1443–1453, March 2014. URL: http://dx.doi.org/10.1002/ajmg.a.36489, doi:10.1002/ajmg.a.36489. This article has 17 citations.](https://doi.org/10.1002/ajmg.a.36489)

[9. (Bhattacharyya2013Arylsulfatase) S Bhattacharyya, L Feferman, and J K Tobacman. Arylsulfatase b regulates versican expression by galectin-3 and ap-1 mediated transcriptional effects. Oncogene, 33(47):5467–5476, November 2013. URL: http://dx.doi.org/10.1038/onc.2013.483, doi:10.1038/onc.2013.483. This article has 35 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/onc.2013.483)

[10. (Bhattacharyya2024SARSCoV2) Sumit Bhattacharyya and Joanne K. Tobacman. Sars-cov-2 spike protein-ace2 interaction increases carbohydrate sulfotransferases and reduces n-acetylgalactosamine-4-sulfatase by p38 mapk. Signal Transduction and Targeted Therapy, February 2024. URL: http://dx.doi.org/10.1038/s41392-024-01741-3, doi:10.1038/s41392-024-01741-3. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41392-024-01741-3)

[11. (Karageorgos2007Mutationala) Litsa Karageorgos, Doug A. Brooks, Anthony Pollard, Elizabeth L. Melville, Leanne K. Hein, Peter R. Clements, David Ketteridge, Stuart J. Swiedler, Michael Beck, Roberto Giugliani, Paul Harmatz, James E. Wraith, Nathalie Guffon, Elisa Leão Teles, M. Clara Sá Miranda, and John J. Hopwood. Mutational analysis of 105 mucopolysaccharidosis type vi patients. Human Mutation, 28(9):897–903, September 2007. URL: http://dx.doi.org/10.1002/humu.20534, doi:10.1002/humu.20534. This article has 104 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.20534)

[12. (Jackson1992Feline) Christine E. Jackson, Naoya Yuhki, Robert J. Desnick, Mark E. Haskins, Stephen J. O’Brien, and Edward H. Schuchman. Feline arylsulfatase b (arsb): isolation and expression of the cdna, comparison with human arsb, and gene localization to feline chromosome a1. Genomics, 14(2):403–411, October 1992. URL: http://dx.doi.org/10.1016/s0888-7543(05)80233-2, doi:10.1016/s0888-7543(05)80233-2. This article has 20 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/s0888-7543(05)80233-2)

[13. (Garrido2008Maroteaux–Lamy) Elena Garrido, Bru Cormand, John J. Hopwood, Amparo Chabás, Daniel Grinberg, and Lluïsa Vilageliu. Maroteaux–lamy syndrome: functional characterization of pathogenic mutations and polymorphisms in the arylsulfatase b gene. Molecular Genetics and Metabolism, 94(3):305–312, July 2008. URL: http://dx.doi.org/10.1016/j.ymgme.2008.02.012, doi:10.1016/j.ymgme.2008.02.012. This article has 28 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.ymgme.2008.02.012)

[14. (Tomanin2018Mucopolysaccharidosis) Rosella Tomanin, Litsa Karageorgos, Alessandra Zanetti, Moeenaldeen Al-Sayed, Mitch Bailey, Nicole Miller, Hitoshi Sakuraba, and John J. Hopwood. Mucopolysaccharidosis type vi (mps vi) and molecular analysis: review and classification of published variants in thearsbgene. Human Mutation, 39(12):1788–1802, September 2018. URL: http://dx.doi.org/10.1002/HUMU.23613, doi:10.1002/humu.23613. This article has 68 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/HUMU.23613)